Trial
NCT04535817
Xolair Interventional Study in ASD Patients With Comorbid Atopy
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Novartis
Condition
Autism Spectrum Disorder
Intervention
Omalizumab Injection [Xolair]
Why stopped
We are terminating due to loss of funding because of Covid-19.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-18